Synthesis and Diels-Alder Reactivity of ortho-Carbazolequinones

Muriel Compain-Batissou, Djamila Latreche, Jacques Gentili, Nadia Walchshofer, and Zouhair Bouaziz*

Laboratoire de Chimie Organique, Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon1; 8 avenue Rockefeller, 69373 Lyon cedex 08, France. Received February 2, 2004; accepted June 9, 2004

Oxidation of 2- and 3-hydroxycarbazoles with Frémy's salt gave the corresponding *ortho*-carbazolequinones. These molecules react as carbodienophiles in Diels–Alder reaction with 1-acetoxy-1,3-butadiene and 1,3-cy-clopentadiene to provide the novel benzocarbazolequinone structures 15, 16, 18 and 19.

Key words ortho-carbazolequinone; Diels-Alder reaction; benzocarbazolequinone

The carbazole-3,4-quinones represent an important family of carbazole alkaloids. Carquinostatins A and B, lavanduquinocin and carbazoquinocins A—F represent the first carbazole alkaloids containing an *ortho*-quinone system¹⁾ and possess various biologic activities (Chart 1).

The carquinostatins A and B were isolated from *Strepto-myces exfoliatus 2419-SVT2* and were shown to be potent neuronal protecting substances.^{2,3)} Lavanduquinocin was isolated from *Streptomyces viridochromogenes 2942-SVS3* and exhibit a strong neuronal cell protecting activity.⁴⁾ The carbazoquinocins A—F were isolated from *Streptomyces violaceus 2448-SVT2* and they showed strong inhibitory activity against lipid peroxydation.⁵⁾

As part of our continuing search for biologically active compounds with a quinone moiety, we were particularly interested in the synthesis and in the Diels–Alder chemistry of carbazolequinones.⁶⁾ In a previous work we reported the synthesis,^{7,8)} the induction of caspase-dependent cell death⁹⁾ and the *Toxoplasma gondii* purine nucleoside phosphorylase inhibitory activity¹⁰⁾ of some carbazole-1,4-quinones.

The purpose of this work is to obtain carbazole-1,2 and -3,4-dione derivatives and to report their behaviour as dienophiles in [4+2] cycloaddition reactions.

Results and Discussion

Carbazole-1,2-quinone 3^{11} was obtained by oxidation of the commercially available hydroxycarbazole 1 with Frémy's salt. Treatment of 1 with sodium hydride in the presence of methyl iodide in the solvent system THF–DMF, gave



Chart 1

* To whom correspondence should be addressed. e-mail: bouaziz@univ-lyon1.fr

chemoselectively the *N*-methylated compound $2^{(12)}$. Then, oxidation of 2 with Frémy's salt afforded carbazole-1,2-quinone 4.

On the other hand, carbazole-3,4-quinone 7 was obtained in two steps from the commercially available 3-aminocarbazole 5. The formation of the corresponding diazonium salt at 0 °C followed by heating the latter in highly acidic aqueous solution gave the 3-hydroxycarbazole 6, which was oxidized as above to yield quinone 7 (Chart 2).

Our attempts to obtain 7 through a direct oxidation of 5 with Frémy's salt provided the dimeric carbazole compounds 12 and 13 only. The reaction may proceed first by formation of a mixture of amino phenol 8 and *ortho*-quinone imine 9. Then, a nucleophilic addition of primary amine 5 or 8 to quinone imine 9 led to intermediates 10 and 11 which were subsequently oxidized to the dimeric carbazoles 12 and 13 (Chart 3). Aromatic amines which have a position *para* to the amino group substituted by an alkyl or alkoxy group have been reported to undergo a similar reaction.^{13,14}



© 2004 Pharmaceutical Society of Japan





The Diels–Alder reactions of *ortho*-quinones previously reported have been essentially performed with carbodienes. Recently, our group reported the first examples of [4+2] cy-cloaddition of *ortho*-benzofurandione¹⁵⁾ and *ortho*-indolo-quinone¹⁶⁾ towards 1-azadienes. Thus the *ortho*-benzofurandione reacts as a carbodienophile and *ortho*-indoloquinone can react either as a carbodienophile or as heterodienophile.

In continuation of this work focused on heterocyclic *ortho*-quinones we planned to investigate the chemical behaviour of *ortho*-carbazolequinones **3** and **7** towards carbodienes and 1-azadienes.

The [4+2] cycloaddition between carbazolequinone **3** or **7** and 1-acetoxy-1,3-butadiene **14** was performed at reflux in dry THF and provided directly the benzocarbazolequinones **15** and **16**, respectively. The reaction between 1,3-cyclopentadiene **17** and carbazolequinone **3**, carried out in dichloromethane at $-10 \,^{\circ}$ C for 5 h then at room temperature for 12 h led to the stable cycloadduct endo **18**. In contrast, reaction of **7** with 1,3-cyclopentadiene **17** as above gave an unstable tetrahydro cycloadduct which was converted into the dihydro derivative **19** after its treatment with silicagel at 40 °C (Chart 4).

The stereochemistry endo of **18** was confirmed by ¹H-NMR NOE DIFF experiment (Chart 5). Irradiation at 3.42 ppm (H-4a) gives responses on H-11c at 4.12 ppm and H-12 at 1.71 ppm. Irradiation at 4.12 ppm (H-11c) gives responses on H-4a and H-12. Finally, an irradiation at 1.71 ppm (H-12) gives two responses on H-4a and H-11c.

Attempted cycloadditions of *ortho*-carbazolequinones **3** and **7**, as dienophiles, with different 1-azadienes gave a complex mixture of products and failed to yield the expected pyridocarbazolequinones, probably due to the versatile reactivity profile of *ortho*-quinones in Diels–Alder reactions. Potentially they can react as carbodienes, heterodienes or dienophiles.

Experimental

Melting points were taken in a capillary tube using a Büchi 510 apparatus. The IR spectra were obtained on a Perkin–Elmer 1310 spectrophotometer. The NMR spectra were recorded with a Bruker AM 300 spectrometer (¹H-NMR: 300 MHz, ¹³C-NMR: 75 MHz). Chemical shifts are reported in ppm using tetramethylsilane (TMS) as an internal reference. Coupling constant values are given in Hz. Elemental analyses were performed at the Centre de Microanalyse du CNRS at Solaize, France.

2-Hydroxy-9-methyl-9*H***-carbazole (2)** A solution of 2-hydroxycarbazole **1** (0.457 g, 2.5 mmol) and DMF (0.37 ml, 4.76 mmol) in dry THF (5 ml) was added dropwise to 60% NaH (0.25 g, 6.25 mmol) under a nitrogen atmosphere and stirring at room temperature. After 10 min, CH₃I (0.17 ml, 2.75 mmol) was added and the stirring was continued for 2 h. The resulting mixture was cooled to 0 °C and quenched with water (2 ml). After removing the solvent under vacuum, the crude product was washed with acidic aqueous solution and purified by column chromatography on silica gel with CH₂Cl₂/MeOH (98 : 2) as the eluent. Compound **2** was obtained as a yellow solid in 80% yield (ref. 12, 89%), mp 162 °C (ref. 12, 166–167 °C). IR (KBr) cm⁻¹: 3360. ¹H-NMR (DMSO-*d*₆) δ : 9.53 (1H, s, OH), 7.96 (1H, d, *J*=7.7 Hz, H-5), 7.89 (1H, d, *J*=8.3 Hz, H-4), 7.48 (1H, d, *J*=8.2, L1.Hz, H-7), 7.13 (1H, td, *J*=7.7, 1.0 Hz, H-6), 6.86 (d, 1H, *J*=2.0 Hz, H-1), 6.68 (1H, dd, *J*=8.3, 2.0 Hz, H-3), 3.76 (3H, s, CH₃-9).

General Method for the Oxidation of Hydroxycarbazoles with Frémy's Salt An aqueous solution (20 ml) of Frémy's salt (0.37 g, 1.37 mmol) and potassium dihydrogen orthophosphate (0.02 g, 0.15 mmol) was added to a solution of hydroxycarbazole 1, 2 or 6 (0.55 mmol) in acetone (20 ml). The reaction mixture was stirred at room temperature for 30 min, extracted with CH_2Cl_2 , dried over Na_2SO_4 and concentrated under vacuum.

1,2-Dihydrocarbazole-1,2(9*H***)-dione (3)** The quinone **3** was obtained from hydroxycarbazole **1**. The crude mixture was purified by column chromatography on silica gel using CH₂Cl₂/MeOH (95:5) as the eluent. Compound **3** was obtained as a dark green solid in 64% yield (ref. 11, 83%), mp 181 °C (ref. 11, 178 °C). IR (KBr) cm⁻¹: 3260, 1665, 1640. ¹H-NMR (DMSO- d_6) δ : 12.61 (1H, s, NH), 7.87 (2H, m, H-4, H-5), 7.43—7.18 (3H, m, H-6, H-7, H-8), 5.97 (1H, d, J=9.9 Hz, H-3).

9-Methyl-1,2-dihydrocarbazole-1,2(9*H***)-dione (4)** The quinone **4** was obtained from hydroxycarbazole **2**. The crude mixture was purified by column chromatography on silica gel using CH_2Cl_2 as the eluent. Compound **4** was obtained as a dark green solid in 42% yield, mp 177 °C. IR (KBr) cm⁻¹: 1670, 1640. ¹H-NMR (DMSO- d_6) δ : 7.90 (2H, m, H-4, H-5), 7.59 (1H, d, J=8.7 Hz, H-8), 7.45 (1H, m, H-6 or H-7), 7.26 (1H, m, H-6 or H-7), 6.01 (1H, d, J=9.8 Hz, H-3), 4.01 (3H, s, CH_3 -9). ¹³C-NMR (DMSO- d_6) δ : 182.7, 172.4, 141.2, 138.2, 131.2, 128.6, 123.9, 123.8, 123.3, 121.9, 112.7, 32.6. HR-MS *m/z*: 211.0630 (Calcd for C₁₃H₉NO₂: 211.0633).

3-Hydroxy-9-ethyl-9H-carbazole (6) A solution of 3-amino-9-ethylcarbazole 5 (1 g, 4.76 mmol), ice (3 g) and concentrated H₂SO₄ (1 ml) in water (1.5 ml) was stirred at 0 °C. Then, a cooled solution of NaNO₂ (0.391 g, 5.11 mmol) in water (1 ml) was added dropwise and the stirring was continued for 10 min. The resulting mixture was added to acidic aqueous solution (3 ml of concentrated H2SO4 in 2.5 ml of water) heated at reflux. After 5 min the reaction mixture was poured into ice water (30 ml), extracted with CH2Cl2 and dried with Na2SO4. After removing the solvent under vacuum, the crude product was purified by column chromatography on silica gel with CH₂Cl₂ as the eluent. Compound 6 was obtained as a beige solid in 15% yield, mp 106 °C. IR (KBr) cm⁻¹: 3300. ¹H-NMR (CDCl₃) δ : 8.03 (1H, d, J=7.7, 1.1 Hz, H-5), 7.54 (1H, d, J=2.3 Hz, H-4), 7.47 (1H, td, J=8.3, 1.1 Hz, H-7), 7.38 (1H, d, J=8.3 Hz, H-8), 7.27 (1H, d, J=8.7 Hz, H-1), 7.19 (1H, td, J=7.7, 1.1 Hz, H-6), 7.04 (1H, dd, J=8.7, 2.3 Hz, H-2), 4.85 (1H, s, OH), 4.33 (2H, q, J=7.3 Hz, CH₂CH₃), 1.42 (3H, t, J=7.3 Hz, CH₂CH₃). Anal. Calcd for C₁₄H₁₃NO · 0.4 H₂O: C, 76.97; H, 6.37; N, 6.41. Found: C, 77.16; H, 6.40; N, 6.23.

9-Ethyl-3,4-dihydrocarbazole-3,4(9*H***)-dione (7)** The quinone 7 was obtained from hydroxycarbazole **6** by oxidation with Frémy's salt according to the general method described above. The crude mixture was purified by column chromatography on silica gel using $CH_2Cl_2/MeOH$ (99.5 : 0.5) as the eluent. Compound 7 was obtained as a red solid in 50% yield, mp 195 °C. IR (KBr) cm⁻¹: 1670, 1640. ¹H-NMR (CDCl₃) δ : 8.09 (1H, m, H-5), 7.31–7.15 (4H, m, H-1, H-6, H-7, H-8), 6.16 (1H, d, J=10.2 Hz, H-2), 4.14 (2H, q, J=7.4 Hz, CH_2CH_3), 1.43 (3H, t, J=7.4 Hz, CH_2CH_3). ¹³C-NMR (DMSO- d_6) δ : 184.7, 173.2, 143.9, 138.4, 131.9, 129.5, 126.3, 125.6, 125.5, 121.6, 113.5, 113.1, 39.3, 16.7. *Anal.* Calcd for C₁₄H₁₁NO₂·0.3 H₂O: C, 72.90; H, 5.07; N, 6.07. Found: C, 72.81; H, 4.90; N, 6.07.

Oxidation of 3-Amino-9-ethylcarbazole 5 with Frémy's Salt An aqueous solution (200 ml) of Frémy's salt (3.2 g, 11.9 mmol) and potassium dihydrogen orthophosphate (0.16 g, 1.19 mmol) was added to a solution of aminocarbazole **5** (1 g, 4.76 mmol) in acetone (200 ml). The reaction mixture was stirred at room temperature for 1 h, extracted with CH_2Cl_2 , dried over MgSO₄ and concentrated under vacuum. The crude residue was purified by column chromatography on silica gel using $CH_3COOEt/Petroleum$ ether (20:80) as the eluent to give compounds **12** and **13**.

3-Amino-9-ethyl-1-[(9-ethyl-9*H***-carbazol-3-yl)imino]-1,9-dihydro-4***H***-carbazol-4-one (12) Compound 12 was obtained as a dark red solid in 10% yield, mp 236 °C. IR (KBr) cm⁻¹: 3460, 3360, 1635, 1595. ¹H-NMR (DMSO-d_0) \delta: 8.19 (2H, d, J=7.4 Hz, H), 7.77 (1H, d, J=7.4 Hz), 7.76 (1H, s, H-4'), 7.68 (1H, d, J=8.5 Hz), 7.62 (1H, d, J=8.5 Hz), 7.49—7.33 (3H, m), 7.21—7.13 (2H, m), 6.34 (2H, br s, NH₂), 5.93 (1H, s, H-2), 4.96 (2H, q, J=7.0 Hz, CH₂CH₃), 1.36 (3H, t, J=7.0 Hz, CH₂CH₃), 1.45 (3H, t, J=7.0 Hz, CH₂CH₃), 1.36 (3H, t, J=7.0 Hz, CH₂CH₃).** *Anal.* **Calcd for C₂₈H₂₄N₄O · 0.4 H₂O: C, 76.48; H, 5.68; N, 12.74. Found: C, 76.51; H, 5.73; N, 12.59.**

3-Amino-9-ethyl-1-[(9-ethyl-4-hydroxy-9*H***-carbazol-3-yl)imino]-1,9dihydro-4***H***-carbazol-4-one (13) Compound 13 was obtained as a dark blue solid in 30% yield, mp 248 °C. IR (KBr) cm⁻¹: 3500, 3380, 1625, 1585, 1550. ¹H-NMR (DMSO-d_6) \delta: 9 (1H, s, OH), 8.26 (1H, d,** *J***=7.4 Hz), 8.19 (1H, d,** *J***=7.4 Hz), 7.75 (1H, d,** *J***=8.1 Hz), 7.57 (1H, d,** *J***=8.1 Hz), 7.44— 7.32 (3H, m), 7.19 (1H, m), 7.14 (1H, d,** *J***=8.5 Hz), 7.01 (1H, d,** *J***=8.5 Hz), 6.32 (2H, br s, NH₂), 6.04 (1H, s, H-2), 5.03 (2H, q,** *J***=7.0 Hz, <u>CH₂CH₃), 4.42</u> (2H, q,** *J***=7.4 Hz, <u>CH₂CH₃), 1.41 (3H, t,** *J***=7.4 Hz, CH₂CH₃), 1.35 (3H, t,** *J***=7.0 Hz, CH₂<u>CH₃). FAB-MS** *m/z* **449 (M+H)⁺.** *Anal.* **Calcd for C₂₈H₂₄N₄O₂: 0.4 H₂O: C, 73.79; H, 5.49; N, 12.29. Found: C, 73.87; H, 5.41; N, 12.36.**</u></u>

Benzo[c]carbazole-5,6(7*H***)-dione (15) 1-Acetoxy-1,3-butadiene 14 (0.503 g, 4.5 mmol) in dry THF (1 ml) was added dropwise to a solution of carbazoledione 3 (0.3 g, 1.52 mmol) in 14 ml of the same solvent. The reaction mixture was stirred at reflux for 15 h. The solvent was evaporated off to afford a residue which was purified by column chromatography on silica gel with CH₂Cl₂/MeOH (95:5) as the eluent to give compound 15** as a black solid in 56% yield, mp >300 °C. IR (KBr) cm⁻¹: 3320, 1710, 1680. ¹H-NMR (CDCl₃) &: 12.4 (1H, s, NH), 8.29 (1H, d, *J*=8.3 Hz), 8.18 (1H, d, *J*=7.6 Hz), 7.89 (1H, dd, *J*=7.5, 1.3 Hz), 7.68 (1H, td, *J*=7.6, 1.3 Hz), 7.44 (2H, m), 7.34 (1H, td, *J*=7.5, 1.0 Hz), 7.25 (1H, td, *J*=6.6, 1.5 Hz). ¹³C-NMR (DMSO-d₆) &: 181.5, 172.3, 141.0, 136.4, 135.7, 132.9, 130.6, 130.5, 128.5, 127.9, 125.6, 123.9, 123.8, 123.3, 122.2, 114.7. *Anal.* Calcd for C₁₆H₉NO₂·0.3 H₂O: C, 76.06; H, 3.83; N, 5.54. Found: C, 76.38; H, 4.05; N, 5.55.

11-Ethylbenzo[a]carbazole-5,6(11*H***)-dione (16)** Synthesis of compound **16** was performed starting from 7 following the procedure used for **15**. Compound **16** was purified by column chromatography on silica gel with CH₂Cl₂/MeOH (98:2) as the eluent and obtained as an orange solid in 35% yield, mp 255 °C. IR (KBr) cm⁻¹: 1690, 1630. ¹H-NMR (CDCl₃) & 8.30 (1H, dd, J=6.6, 1.8 Hz), 8.16 (1H, dd, J=7.6, 1.0 Hz), 7.80 (1H, d, J=7.9 Hz), 7.68 (1H, td, J=7.6, 1.3 Hz), 7.46 (1H, t, J=7.4 Hz), 7.40—7.28 (3H, m), 4.59 (2H, q, J=7.3 Hz, <u>CH₂CH₃</u>), 1.69 (3H, t, J=7.3 Hz, CH₂<u>CH₃</u>). ¹³C-NMR (DMSO-d₆) & 182.4, 174.5, 151.3, 143.6, 139.7, 136.3, 132.1, 131.2, 130.8, 129.9, 125.9, 125.82, 125.2, 121.9, 115.1, 112.4, 41.5, 15.6. *Anal.* Calcd for C₁₈H₁₃NO₂·0.25 H₂O: C, 77.26; H, 4.86; N, 5.00. Found: C, 77.31; H, 4.80; N, 4.78.

1,4,4a,11c-Tetrahydro-1,4-methanobenzo[c]carbazole-5,6(7H)-dione (18) Freshly distilled cyclopentadiene 17 (1.05 g, 15.9 mmol) was added dropwise to a solution of the carbazoledione 3 (1 g, 5.3 mmol) in CH_2Cl_2 (40 ml) stirred and cooled at -10 °C. The stirring was continued for 5 h at -10 °C then for 12 h at room temperature. The solution was concentrated under vacuum and the resulting residue was chromatographed on silica gel using CH₂Cl₂/MeOH (97:3) as the eluent. Compound 18 was obtained as a yellow solid in 49% yield, mp 182 °C. IR (KBr) cm⁻¹: 3260 1700, 1640. ¹H-NMR (CDCl₃) δ : 8.9 (1H, s, NH), 7.87 (1H, d, *J*=7.9 Hz, H-11), 7.55—7.20 (3H, m, H-8, H-9, H-10), 6.1 (1H, t, *J*=5.3, 3.0 Hz, H-2 or H-3), 5.58 (1H, t, *J*=5.3, 3.0 Hz, H-2 or H-3), 4.1 (1H, dd, *J*=7.2, 3.8 Hz, H-11c), 3.59 (2H, s, H-1, H-4), 3.42 (1H, dd, *J*=7.2, 3.8 Hz, H-4a), 1.71 (2H, s, H-12). ¹³C-NMR (DMSO-*d*₆) δ : 199.1, 172.2, 140.8, 136.3, 135.2, 134.9, 129.4, 126.1, 124.6, 123.4, 121.4, 113.9, 51.5, 49.8, 49.1, 48.2, 37.4. *Anal.* Calcd for C₁₇H₁₃NO₂·0.7 H₂O: C, 74.00; H, 5.26; N, 5.07. Found: C, 73.98; H, 4.89; N, 5.23.

11-Ethyl-1,4-dihydro-1,4-methanobenzo[a]carbazole-5,6(11H)-dione (19) Freshly distilled cyclopentadiene 17 (0.4 g, 6.06 mmol) was added dropwise to a solution of the carbazoledione 7 (0.15 g, 0.67 mmol) in CH₂Cl₂ (6 ml) stirred and cooled at 0 °C. The stirring was continued for 6 h at 0 °C. Then, 1.5 g of SiO₂ was added and the reaction mixture was stirred for 48 h at 40 °C. The mixture was filtered and SiO₂ washed with CH₂Cl₂. The combined filtrates were concentrated under vacuum. Column chromatography of the residue, eluting with a mixture of CH₂Cl₂/MeOH (98:2) gave compound 19 as a dark green solid in 26% yield, mp 191 °C (decomp.). IR (KBr) cm⁻¹: 1625. ¹H-NMR (CDCl₃) δ : 8.15 (1H, m, J=7.9, 1.1 Hz, H-7), 7.34-7.25 (3H, m, H-8, H-9, H-10), 6.96 (1H, dd, J=4.9, 3.2 Hz, H-2 or H-3), 6.82 (1H, dd, J=4.9, 3.2 Hz, H-2 or H-3), 4.45 (2H, q, J=7.4 Hz, CH₂CH₂), 4.33 (1H, s, H-1 or H-4), 4.16 (1H, s, H-1 or H-4), 2.36 (2H, m, $\overline{\text{H-12}}$), 1.58 (3H, t, J=7.4 Hz, CH₂CH₃). ¹³C-NMR (DMSO- d_6) δ : 178.6, 176.4, 160.9, 151.4, 151.2, 144.4, 141.2, 138.8, 126.8, 125.6, 125.3, 121.2, 112.7, 111.3, 71.0, 52.3, 47.8, 17.1. Anal. Calcd for C₁₉H₁₅NO₂·0.5 H₂O: C, 76.49; H, 5.41; N, 4.69. Found: C, 76.56; H, 5.29; N, 4.67.

Acknowledgments We thank Pr. Houda Fillion for her encouragement and for the help she has given us in the preparation of the manuscript.

References

- 1) Knölker H.-J., Reddy K. R., Chem. Rev., 102, 4303-4427 (2002).
- Shin-ya K., Tanaka M., Furihata K., Hayakawa Y., Seto H., *Tetrahe*dron Lett., 34, 4943—4944 (1993).
- Shin-ya K., Kunigami T., Kim J.-S., Furihata K., Hayakawa Y., Seto H., *Biosci. Biotech. Biochem.*, 61, 1768–1769 (1997).
- Shin-ya K., Shimizu S., Kunigami T., Furihata K., Seto H., J. Antibiot., 48, 574—578 (1995).
- Tanaka M., Shin-ya K., Furihata K., Seto H., J. Antibiot., 48, 326– 328 (1995).
- Bouaziz Z., Nebois P., Poumaroux A., Fillion H., *Heterocycles*, 52, 977–999 (2000).
- Poumaroux A., Bouaziz Z., Domard M., Fillion H., *Heterocycles*, 45, 585–596 (1997).
- Poumaroux A., Bouaziz Z., Fillion H., Domard M., Giraud J., Pétavy A.-F., Chem. Pharm. Bull., 47, 643–646 (1999).
- Aouacheria A., Néel B., Bouaziz Z., Dominique R., Walchshofer N., Paris J., Fillion H., Gillet G., *Biochem. Pharmacol.*, 64, 1605–1616 (2002).
- Bouaziz Z., Ghérardi A., Régnier F., Sarciron M.-E., Bertheau X., Fenet B., Walchshofer N., Fillion H., *Eur. J. Org. Chem.*, **11**, 1834– 1838 (2002).
- 11) Teuber H.-J., Staiger G., Chem. Ber., 87, 1251-1254 (1954).
- Albanese D., Landini D., Penso M., Spano G., Trebicka A., *Tetrahedron*, **51**, 5681—5688 (1995).
- 13) Teuber H.-J., Jellinek G., Chem. Ber., 87, 1841-1848 (1954).
- 14) Horner L., Sturm K., Chem. Ber., 88, 329–338 (1955).
- Nebois P., Cherkaoui O., Benameur L., Fillion H., Fenet B., *Tetrahe*dron, 50, 8457–8464 (1994).
- 16) Bernardes Genisson V., Nebois P., Domard M., Fillion H., Chem. Pharm. Bull., 48, 893-894 (2000).